StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock analysis

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.56+0.17 (+3.87%)

Close on Nov 17, 2026Market cap $508.49MP/E –Yield –

StockData Score

Prices as of Nov 17, 2026How the score works

Value1Growth1Performance3Health6Dividend0

Mixed11 of 30 checks passed

Gyre Therapeutics passes 11 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
1/6
Growth
1/6
Past performance
3/6
Financial health
6/6
Dividend
0/6

What stands out

  • Trading below fair value

    The share price of $4.56 is below our fair value estimate of $5.29.

  • No debt

    Gyre Therapeutics has no borrowings on its latest balance sheet.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Margin of safety under 20%

    The price is 13.8% below fair value, less than the 20% cushion we look for.

  • Return on equity under 15%

    Return on equity was -34.9% over the last twelve months and averaged -138% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -26.6%, below the 10% that usually covers the cost of capital.

  • Revenue growing under 10% a year

    Revenue grew 4.5% a year over the last three fiscal years, short of the 10% we look for.

Valuation1/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Gyre Therapeutics's price-to-book of 4.71 is above the Drugs median of 2.15.

  • Trading below fair value

    The share price of $4.56 is below our fair value estimate of $5.29.

  • Margin of safety under 20%

    The price is 13.8% below fair value, less than the 20% cushion we look for.

Growth1/6
  • Revenue growing under 10% a year

    Revenue grew 4.5% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -12.6% a year over the last three fiscal years.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -3.7% over the last twelve months; the Drugs median is 6.5%.

  • Guidance unchanged

    The latest outlook (Full year 2026 revenue guidance, Nov 5, 2026) was maintained, so it neither adds nor takes away points.

  • Gross margin improving

    Gross margin was 93.4% over the last twelve months, against 91.2% a year earlier.

Past performance3/6
  • Return on equity under 15%

    Return on equity was -34.9% over the last twelve months and averaged -138% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -26.6%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Gyre Therapeutics's return on equity of -34.9% is above the Drugs median of -59.0%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -33.9% over the last twelve months, against a 5-year average of -249%.

  • Net margin above the industry

    Gyre Therapeutics's net margin of -33.9% is above the Drugs median of -59.9%.

Financial health6/6
  • No debt

    Gyre Therapeutics has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 4.32 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 8.53; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    Gyre Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$5.29

The share price is 14% below this estimate.

20%+ below
Near fair value
20%+ above
$4.56Price$5.29Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B4.6×8.1×2.2×$4.4350%
P/S6.3×8.2×5.1×$6.1550%
Earnings powerleft out, too far from the others11.2% cost of equity––$0.52–
Fair value$5.29100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Drugs median 21.8

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$986.37K
Value traded per 1% price move
$250.22K

Downside

High risk

Typical loss in a bad month
35.0%
Volatility (annualized)
67%
Sharpe ratio, 1 year
-0.71
Beta to the S&P 500 (5Y)
1.21

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

95.4%

Operating margin

9.9%+283.7 pts over 5 years

Net margin

8.5%+277.0 pts over 5 years

See a number that looks wrong?